CTKB - Cytek Biosciences Inc. Reports Q1 Loss Tops Revenue Estimates | Benzinga
Cytek Biosciences, Inc. (NASDAQ: CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 80%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.07, delivering a surprise of 133.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Cytek Biosciences, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $44.86 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 2.28%. This compares to year-ago revenues of $37.09 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Cytek ...